P46.04 Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants

MLA

Nakanishi, Y., et al. “P46.04 Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants.” Journal of Thoracic Oncology, vol. 16, no. 10, Number 10 Supplement 1, Oct. 2021, pp. S1094–95. EBSCOhost, https://doi.org/10.1016/j.jtho.2021.08.490.

APA

Nakanishi, Y., Ohishi, Y., Iida, Y., Nakagawa, Y., Shimizu, T., Tsujino, I., Hirotani, Y., Tanino, T., Nishimaki, H., Kobayashi, H., Nozaki, F., Ohni, S., Tang, X., Gon, Y., & Masuda, S. (2021). P46.04 Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants. Journal of Thoracic Oncology, 16(10, Number 10 Supplement 1), S1094–S1095. https://doi.org/10.1016/j.jtho.2021.08.490

Chicago

Nakanishi, Y., Y. Ohishi, Y. Iida, Y. Nakagawa, T. Shimizu, I. Tsujino, Y. Hirotani, et al. 2021. “P46.04 Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants.” Journal of Thoracic Oncology 16 (10, Number 10 Supplement 1): S1094–95. doi:10.1016/j.jtho.2021.08.490.